share_log

Mangoceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Cohen Jacob D.

Mangoceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Cohen Jacob D.

Mangoceuticals | 4:持股變動聲明-高管 Cohen Jacob D.
美股SEC公告 ·  06/05 17:17
Moomoo AI 已提取核心訊息
Jacob D. Cohen, the Chief Executive Officer of Mangoceuticals, Inc. (MGRX), completed a significant stock transaction on June 3, 2024. Cohen was granted 800,000 shares of common stock at no cost, as per the transaction details released. Following this grant, Cohen directly holds a total of 800,000 shares in the company. The transaction, which was classified as a grant, indicates a strengthening of the CEO's stake in Mangoceuticals, potentially signaling confidence in the company's future prospects.
Jacob D. Cohen, the Chief Executive Officer of Mangoceuticals, Inc. (MGRX), completed a significant stock transaction on June 3, 2024. Cohen was granted 800,000 shares of common stock at no cost, as per the transaction details released. Following this grant, Cohen directly holds a total of 800,000 shares in the company. The transaction, which was classified as a grant, indicates a strengthening of the CEO's stake in Mangoceuticals, potentially signaling confidence in the company's future prospects.
Mangoceuticals公司的執行長Jacob D. Cohen於2024年6月3日完成了一筆重要的股票交易。根據釋出的交易細節,Cohen免費獲得了80萬股普通股。在此資助之後,Cohen直接持有公司的80萬股。此交易被歸類為資助,表明公司內Cohen的利益增強,可能預示著對公司未來前景的信懇智能。
Mangoceuticals公司的執行長Jacob D. Cohen於2024年6月3日完成了一筆重要的股票交易。根據釋出的交易細節,Cohen免費獲得了80萬股普通股。在此資助之後,Cohen直接持有公司的80萬股。此交易被歸類為資助,表明公司內Cohen的利益增強,可能預示著對公司未來前景的信懇智能。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息